The effect of combination of rosuvastatin and fenofibrate and metoprolol on the coronary atheroma plaque progression detected by multi-detector spiral computed tomography

Phase 4

• Conditions: coronary artery disease; hyperlipidemia; Cardiovascular - Coronary heart disease; Metabolic and Endocrine - Other metabolic disorders

• Registration Number: ACTRN12611000394943
• Lead Sponsor: Peking University Health Science Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-04-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 520

Inclusion Criteria

1.no chest pain or atypical chest pain
2.mild to moderate coronary atheroma plaque by multidetector computed tomography (MDCT)
3. diameter narrowing is less than 50%
4. low-density lipoprotein cholesterol(LDL-C)>100mg/dl, triglyceride(TG)>150 mg/d

Exclusion Criteria

known coronary artery disease; previous coronary revascularization; signs or symptoms suggesting ischemia and coronary revascularization needed in a short time; current lipid-lowering pharmacotherapy; known genetic form of dyslipidemia; creatinine > 1.5 mg/dL; ALT or AST>40u/L; fasting serum TG> 500 mg/dL; inability to perform MDCT; uncontrolled hypertension; decompensated heart failure (class IV); known pregnancy; combined condition decreasing life expectancy; heart rate<60 beats/min; sick sinus syndrome; atrioventricular block over 2 degree type 2

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the change of atheroma plaque volume is assessed by coronary computed tomography angiography[6 month];the change of CT attenuation value is assessed by coronary computed tomography angiography[6 month];major cardiovascular events(death, myocardial infarction, coronary revascularization, rehospitalization driven by symptom)[6 month]